How can we help you?
We'll help you navigate and understand the emerging ISPOR/ISPE Real World Evidence guidelines.
Watch this webinar where our experts discuss different approaches for developing rigorous economic model structures for rare diseases.
This webinar, based on PRO labeling of cancer treatment drugs, examines trends in EMA and FDA labeling based on patient-reported outcomes (PROs).
In response to the COVID-19 pandemic, we are taking measures to protect the health of our staff while providing uninterrupted service to our clients.
Navigate the ever-evolving landscape of benefit-risk assessment and meet the requirements of regulatory and reimbursement stakeholders worldwide.
The paradigm of regenerative medicine development is changing. Our experienced team can help you stay on track.